In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 275 of 379

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke	HealthTech guidance	11 February 2027
Percutaneous thrombectomy for intermediate-risk and high-risk acute pulmonary embolism	HealthTech guidance	7 April 2027
Perioperative care in adults	Quality standard	1 July 2026
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
Pharmalgen for the treatment of bee and wasp venom allergy	Technology appraisal guidance	TBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]	Technology appraisal guidance	TBC
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]	Technology appraisal guidance	1 July 2026
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]	Technology appraisal guidance	TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]	Technology appraisal guidance	17 September 2026
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]	Technology appraisal guidance	17 September 2026
Polyendocrine Metabolic Ovarian Syndrome (PMOS)	NICE guideline	9 December 2026
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]	Technology appraisal guidance	13 May 2027
Prostate cancer: diagnosis and management (update)	NICE guideline	17 December 2027
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]	Technology appraisal guidance	TBC
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]	Technology appraisal guidance	TBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]	Technology appraisal guidance	15 November 2017
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]	Technology appraisal guidance	22 October 2026
Renal cell carcinoma Pathways Pilot [ID6186]	Technology appraisal guidance	TBC
Renal sympathetic denervation for resistant hypertension	HealthTech guidance	TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]	Technology appraisal guidance	TBC

Results per page

10
25
50
All